Teladoc Health (NYSE:TDOC - Get Free Report) had its price target boosted by research analysts at Truist Financial from $8.00 to $9.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a "hold" rating on the health services provider's stock. Truist Financial's target price suggests a potential upside of 11.30% from the company's current price.
Other analysts also recently issued research reports about the stock. Stifel Nicolaus lifted their price target on shares of Teladoc Health from $5.50 to $6.50 and gave the company a "hold" rating in a research note on Thursday, October 29th. Deutsche Bank increased their price objective on Teladoc Health from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. Canaccord Genuity Group reduced their price objective on Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. UBS Group lifted their target price on Teladoc Health from $6.50 to $9.00 and gave the company a "neutral" rating in a research report on Monday, November 2nd. Finally, TD Cowen lifted their target price on Teladoc Health from $6.00 to $8.00 and gave the company a "hold" rating in a research report on Monday, November 9th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $8.60.
View Our Latest Stock Analysis on TDOC
Teladoc Health Price Performance
TDOC stock opened at $8.09 on Thursday. The company has a market capitalization of $1.47 billion, a PE ratio of -9.40 and a beta of 2.00. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The firm's 50-day moving average is $6.89 and its 200 day moving average is $6.65.
Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The health services provider reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. The company had revenue of $605.10 million during the quarter, compared to analyst estimates of $588.14 million. Teladoc Health had a negative net margin of 6.27% and a negative return on equity of 11.63%. The firm's revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.28) EPS. Sell-side analysts forecast that Teladoc Health will post -0.86 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Carlos Nueno sold 29,432 shares of the business's stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $9.20, for a total value of $270,774.40. Following the completion of the transaction, the insider owned 35,312 shares of the company's stock, valued at $324,870.40. The trade was a 45.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Charles III sold 17,805 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $6.10, for a total transaction of $108,610.50. Following the completion of the transaction, the chief executive officer directly owned 465,535 shares of the company's stock, valued at $2,839,763.50. This trade represents a 3.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 47,892 shares of company stock worth $383,086. Insiders own 0.70% of the company's stock.
Institutional Trading of Teladoc Health
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in shares of Teladoc Health by 1.3% during the 1st quarter. Renaissance Technologies LLC now owns 8,085,542 shares of the health services provider's stock worth $44,066,000 after purchasing an additional 107,400 shares during the last quarter. Monaco Asset Management SAM purchased a new position in Teladoc Health in the second quarter valued at about $26,864,000. Pale Fire Capital SE grew its stake in Teladoc Health by 74.8% in the first quarter. Pale Fire Capital SE now owns 3,398,491 shares of the health services provider's stock valued at $18,522,000 after purchasing an additional 1,454,288 shares during the last quarter. Quantinno Capital Management LP raised its holdings in Teladoc Health by 128.0% in the first quarter. Quantinno Capital Management LP now owns 2,621,378 shares of the health services provider's stock worth $14,287,000 after purchasing an additional 1,471,631 shares in the last quarter. Finally, Counterpoint Mutual Funds LLC raised its holdings in Teladoc Health by 1,017.4% in the third quarter. Counterpoint Mutual Funds LLC now owns 1,650,165 shares of the health services provider's stock worth $9,571,000 after purchasing an additional 1,502,488 shares in the last quarter. Institutional investors own 76.82% of the company's stock.
About Teladoc Health
(
Get Free Report)
Teladoc Health, Inc. provides virtual healthcare services through a digital platform that connects individuals with clinicians and other health professionals. Its offerings include virtual primary and specialty care, mental health services, and support for managing chronic conditions. The company serves members in the United States and internationally, with services and availability varying by market. Its consumer mental health services include BetterHelp, while its chronic-care programs draw on technology and services developed by Livongo, which Teladoc acquired in 2020.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teladoc Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teladoc Health wasn't on the list.
While Teladoc Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.